ArticleCardiac failure review2017
Neurohormonal Blockade in Heart Failure.
Article in Cardiac failure review, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.European heart journal · 2018Pooled it
- Commentary: Unveiling a Metabolic-Lymphatic Axis in the Pathogenesis of Heart Failure With Preserved Ejection Fraction.Cardiology discovery · 2026Article
- Exploring the Role of Nesprin1 in isoproterenol-induced heart failure: Insights into pathogenesis and therapeutic implications.PloS one · 2026Article
- AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model.Communications medicine · 2025Article
- Counteracting the Mechanisms of Heart Failure is the Most Effective Way to Decongest Patients while Improving Outcomes.Cardiac failure review · 2025Review
- Heart failure: mechanistic insights and precision therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
- Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).International journal of cardiology. Heart & vasculature · 2024Article
- Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023Review
- New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy.International journal of molecular sciences · 2023Review
- Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure.International journal of molecular sciences · 2023Review
- Sodium-glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Single-cell and spatial transcriptomics of the infarcted heart define the dynamic onset of the border zone in response to mechanical destabilization.Nature cardiovascular research · 2022Article
- Review
- Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies.Oxidative medicine and cellular longevity · 2022Review
- Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Review
- Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.Scientific reports · 2021Article
- Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.Heart failure reviews · 2021Review
- Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction.Annals of translational medicine · 2021Review
- Heart rate at discharge in patients with acute decompensated heart failure is a predictor of mortality.European journal of medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key feature of chronic heart failure (HF) is the sustained activation of endogenous neurohormonal systems in response to impaired cardiac pumping and/or filling properties. The clinical use of neurohormonal blockers has revolutionised the care of HF patients over the past three decades. Drug therapy that is active against imbalance in both the autonomic and renin-angiotensin-aldosterone systems consistently reduces morbidity and mortality in chronic HF with reduced left ventricular ejection fraction and in sinus rhythm. This article provides an assessment of the major neurohormonal systems and their therapeutic blockade in patients with chronic HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.